Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.

Seino Y, Yabe D, Sasaki T, Fukatsu A, Imazeki H, Ochiai H, Sakai S

Journal of diabetes investigation13 Jul 2017Cited by 43 (Europe PMC)

PMID28502112PMCIDPMC5835450DOI10.1111/jdi.12694PepBankPUB-28502112

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin lowered HbA1c from baseline at week 52.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin lowered HbA1c after 52 weeks.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at week 52
Study
n = 76
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−0.68%
week 52
Source sentences
Summary
The changes from baseline in glycated hemoglobin, fasting plasma glucose, and bodyweight (mean ± SE) were -0.68 ± 0.10%, -32.1 ± 3.6 mg/dL and -2.71 ± 0.24 kg at week 52, respectively (all, P < 0.001 vs baseline).
1 context sentence(design, population, supporting numbers)
Summary · context
This 52-week, multicenter, open-label, single-arm clinical study enrolled Japanese patients who had inadequate glycemic control with diet/exercise and liraglutide monotherapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2850211201
02HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin lowered fasting plasma glucose from baseline at week 52.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin lowered fasting blood glucose after 52 weeks.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change at week 52
Study
n = 76
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
Fasting plasma glucose change
−32.1 mg/dL
week 52
Source sentences
Summary
The changes from baseline in glycated hemoglobin, fasting plasma glucose, and bodyweight (mean ± SE) were -0.68 ± 0.10%, -32.1 ± 3.6 mg/dL and -2.71 ± 0.24 kg at week 52, respectively (all, P < 0.001 vs baseline).
1 context sentence(design, population, supporting numbers)
Summary · context
This 52-week, multicenter, open-label, single-arm clinical study enrolled Japanese patients who had inadequate glycemic control with diet/exercise and liraglutide monotherapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2850211202
03HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin lowered bodyweight from baseline at week 52.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin lowered body weight after 52 weeks.
Peptide
Liraglutide
Outcome
DecreaseBodyweight change at week 52
Study
n = 76
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Bodyweight change
−2.71 kg
week 52
Source sentences
Summary
The changes from baseline in glycated hemoglobin, fasting plasma glucose, and bodyweight (mean ± SE) were -0.68 ± 0.10%, -32.1 ± 3.6 mg/dL and -2.71 ± 0.24 kg at week 52, respectively (all, P < 0.001 vs baseline).
1 context sentence(design, population, supporting numbers)
Summary · context
This 52-week, multicenter, open-label, single-arm clinical study enrolled Japanese patients who had inadequate glycemic control with diet/exercise and liraglutide monotherapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2850211203
04HumanNot a test of Liraglutide aloneNon-randomized trialSafety outcome
In Japanese adults with type 2 diabetes on liraglutide, adverse events occurred in 65.8% of patients who received luseogliflozin.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide, 65.8% of patients had an adverse event while taking luseogliflozin.
Peptide
Liraglutide
Outcome
Not applicableAdverse events
Study
n = 76
Outcome group
Adverse events · Whole body
Measurements
Adverse events
65.8%
all patients
Source sentences
Summary
Adverse events and adverse drug reactions occurred in 65.8 and 27.6% of patients, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This 52-week, multicenter, open-label, single-arm clinical study enrolled Japanese patients who had inadequate glycemic control with diet/exercise and liraglutide monotherapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2850211208
05HumanNot a test of Liraglutide aloneNon-randomized trialSafety outcome
In Japanese adults with type 2 diabetes on liraglutide, adverse drug reactions occurred in 27.6% of patients who received luseogliflozin.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide, 27.6% of patients had a side effect linked to luseogliflozin.
Peptide
Liraglutide
Outcome
Not applicableAdverse drug reactions
Study
n = 76
Outcome group
Adverse events · Whole body
Measurements
Adverse drug reactions
27.6%
all patients
Source sentences
Summary
Adverse events and adverse drug reactions occurred in 65.8 and 27.6% of patients, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This 52-week, multicenter, open-label, single-arm clinical study enrolled Japanese patients who had inadequate glycemic control with diet/exercise and liraglutide monotherapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2850211209
06HumanNot a test of Liraglutide aloneNon-randomized trialSafety outcome
In Japanese adults with type 2 diabetes on liraglutide, the safety profile of luseogliflozin, including hypoglycemia frequency, was consistent with previous studies with no new safety concerns.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin raised no new safety concerns compared with previous studies.
Peptide
Liraglutide
Outcome
No significant changeOverall safety profile including hypoglycemia
Study
n = 76
Outcome group
Adverse events · Whole body
Source sentences
Summary
The overall safety profile, including frequency of hypoglycemia, was found to be consistent with those of previous studies and there were no new safety concerns.
1 context sentence(design, population, supporting numbers)
Summary · context
This 52-week, multicenter, open-label, single-arm clinical study enrolled Japanese patients who had inadequate glycemic control with diet/exercise and liraglutide monotherapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2850211210
07HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin reduced fat mass from baseline at week 52.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin reduced body fat after 52 weeks.
Peptide
Liraglutide
Outcome
DecreaseFat mass change at week 52
Study
n = 22
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Fat mass change
−2.49 kg
week 52
Source sentences
Summary
Luseogliflozin was associated with greater reductions in fat mass than lean mass at all measuring points (n = 22): fat vs lean mass changes (mean ± SE) at week 52 were -2.49 ± 0.45 kg (P < 0.001 vs baseline) and -0.44 ± 0.26 kg (P = 0.107 vs baseline), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This 52-week, multicenter, open-label, single-arm clinical study enrolled Japanese patients who had inadequate glycemic control with diet/exercise and liraglutide monotherapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2850211204
08HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin did not significantly change lean mass from baseline at week 52.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin did not clearly change lean body mass.
Peptide
Liraglutide
Outcome
No significant changeLean mass change at week 52
Study
n = 22
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Lean mass change
−0.44 kg
week 52
Source sentences
Summary
Luseogliflozin was associated with greater reductions in fat mass than lean mass at all measuring points (n = 22): fat vs lean mass changes (mean ± SE) at week 52 were -2.49 ± 0.45 kg (P < 0.001 vs baseline) and -0.44 ± 0.26 kg (P = 0.107 vs baseline), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This 52-week, multicenter, open-label, single-arm clinical study enrolled Japanese patients who had inadequate glycemic control with diet/exercise and liraglutide monotherapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2850211205
09HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin improved insulin secretion at weeks 12 and 52 compared with baseline.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin improved insulin secretion compared with baseline.
Peptide
Liraglutide
Outcome
IncreaseInsulin secretion
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Insulin secretion and Matsuda Index were also improved at weeks 12 and 52 compared with baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
This 52-week, multicenter, open-label, single-arm clinical study enrolled Japanese patients who had inadequate glycemic control with diet/exercise and liraglutide monotherapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2850211206
10HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin improved the Matsuda Index at weeks 12 and 52 compared with baseline.
In plain wordsIn Japanese adults with type 2 diabetes on liraglutide, adding luseogliflozin improved insulin sensitivity (Matsuda Index) compared with baseline.
Peptide
Liraglutide
Outcome
IncreaseMatsuda Index
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Insulin secretion and Matsuda Index were also improved at weeks 12 and 52 compared with baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
This 52-week, multicenter, open-label, single-arm clinical study enrolled Japanese patients who had inadequate glycemic control with diet/exercise and liraglutide monotherapy.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2850211207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.

Summary

Results from this study10

Studies that did not test the peptide alone10

Version history

Subjects

Publication types

MeSH terms

Keywords